Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06980649 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of BHV-1300 in Graves' Disease

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 17 to 18v13
  2. Site details revised at 1 of 17 sitesv12
  3. Site details revised at 1 of 17 sitesv11
  4. Primary and study completion pushed from Sep 2026 to Sep 2027
    • Trial sites expanded: 13 → 17 locations
    v10
  5. Primary and study completion dates: Mar 2026 to Sep 2026v9
Show 7 earlier versionsHide 7 earlier versions
  1. Study sites: 12 to 13v8
  2. Site details revised at 1 of 12 sitesv7
  3. Site details revised at 1 of 12 sitesv6
  4. Primary completion date: Nov 2025 to Mar 2026v5
  5. Study sites: 7 to 12v4
  6. Primary endpoints: 1 to 2v3 Show 4 more changesShow less
    • Study sites: 1 to 7
    • Start date changed from estimate of May 2025 to Aug 21, 2025
    • Eligibility criteria shortened, about 8 words
    • Secondary endpoints shortened, about 22 words
  7. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.
Trial Details
NCT Number NCT06980649
Lead Sponsor Biohaven Therapeutics Ltd.
Conditions
(from sponsor)		 Graves Disease
Related terms Autoimmune Diseases, Endocrine System Diseases, Graves Disease, Hyperthyroidism, Thyroid Diseases
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov